论文部分内容阅读
目的:对比氮氧化钛生物有效性支架(Titan2-BAS)与雷帕霉素药物洗脱支架(sirolimus-eluting stent,SES)在冠状动脉血运重建方面的临床疗效。方法:冠心病患者141例,根据植入的支架不同分为A组(Titan2-BAS)87例,B组(SES)54例,A组病变内径(3.1±0.4)mm,长度(24±3)mm,B组病变内径(3.0±0.5)mm,长度(22±4)mm,两组无显著差异。均采用经桡动脉或尺动脉途径冠脉血运重建。A组阿司匹林与氯吡格雷治疗1~3月,B组至少12月。计算A,B两组支架病变的通过率、早期支架内血栓发生率及随访MACE发生率(指死亡、急性心肌梗死、靶血管重建等)。结果:A组146处>75%狭窄病变共植入Titan2-BAS 168枚,1枚支架未能通过病变(RCA),通过率99.3%;B组86处病变共植入SES94枚,通过率100%,两组无显著差异。随访1~17(平均5.8)月。两组均无死亡病例;A组无急、晚期血栓。B组1例术后2 d出现支架内血栓;A组1例术后3月行靶血管重建,B组无靶血管重建;两组MACE发生率无显著差异。结论:Titan2-BAS与SES在冠脉血运重建方面的近期及远期疗效相近,Titan2不增加MACE发生率。
Objective: To compare the clinical efficacy of Titan2-BAS with sirolimus-eluting stent (SES) in coronary revascularization. Methods: One hundred and seventy-one patients with coronary heart disease were divided into two groups: 87 cases in group A (Titan2-BAS) and 54 cases in group B (group S). The diameter of group A was (3.1 ± 0.4) mm and the length was 24 ± 3 ) mm. The diameter of the group B was (3.0 ± 0.5) mm and the length was (22 ± 4) mm. There was no significant difference between the two groups. All patients underwent transradial or ulnar artery revascularization. A group aspirin and clopidogrel treatment of 1 to 3 months, B group at least 12 months. The pass rate of stents, the incidence of early stent thrombosis and the follow-up MACE incidence (death, acute myocardial infarction, target vessel reconstruction, etc.) were calculated. RESULTS: A total of 168 Titan2-BAS implants were implanted in Group A at 75% of the stenoses. One stent failed to pass the lesion (RCA) and the pass rate was 99.3%. In Group B, 86 lesions were implanted with SES94, %, No significant difference between the two groups. Follow-up 1 ~ 17 (average 5.8) months. No deaths in both groups; A group without acute and advanced thrombosis. One patient in group B had stent thrombosis 2 days after operation. One patient in group A underwent target vessel revascularization in March and no target vessel reconstruction in group B. There was no significant difference in MACE between the two groups. Conclusion: The short-term and long-term effects of Titan2-BAS and SES in coronary revascularization are similar. Titan2 does not increase the incidence of MACE.